Results Snapshot
Figures in Cr
Standalone - Profit And Loss Results
Mar'26
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
Profit And Loss Analysis Highlights
Net Sales
YoY Growth in year ended Mar 2026 is 32.59% vs 32.48% in Mar 2025
Operating Profit (PBDIT) excl Other Income
YoY Growth in year ended Mar 2026 is 3.17% vs 37.69% in Mar 2025
Interest
YoY Growth in year ended Mar 2026 is 207.53% vs 21.67% in Mar 2025
Profit After Tax
YoY Growth in year ended Mar 2026 is 62.02% vs -28.34% in Mar 2025
Compare Profit and Loss Results of Astrazeneca Phar
Figures in Cr
standalone - Profit And Loss Results
Change(INR)
Change(%)
No of Months
12
12
Operating Income
2,275.00
738.00
1,537.00
208.27%
Less :Inter divisional transfers
0.00
0.00
0.00
0%
Less: Excise
0.00
0.00
0.00
0%
Net Sales
2,275.00
738.00
1,537.00
208.27%
Expenditure (Ex Depriciation)
Stock Adjustments
-488.00
-12.00
-476.00
-3,966.67%
Raw Materials Consumed
1,868.00
241.00
1,627.00
675.10%
Power & Fuel Cost
2.00
13.00
-11.00
-84.62%
Employee Cost
264.00
47.00
217.00
461.70%
Operating Expenses
20.00
27.00
-7.00
-25.93%
General and Administration Expenses
-1.00
-1.00
0.00
0.00%
Selling and Distribution Expenses
124.00
12.00
112.00
933.33%
Cost of Software developments
0.00
0.00
0.00
0%
Miscellaneous Expenses
31.00
17.00
14.00
82.35%
Expenses Capitalised
0.00
0.00
0.00
0%
Total Expenditure
2,013.00
400.00
1,613.00
403.25%
Operating Profit (PBDIT) excl Other Income
262.00
337.00
-75.00
-22.26%
Other Income
28.00
195.00
-167.00
-85.64%
Operating Profit (PBDIT)
290.00
533.00
-243.00
-45.59%
Interest
4.00
0.00
4.00
0%
Profit before Depriciation and Tax
286.00
532.00
-246.00
-46.24%
Depreciation
28.00
25.00
3.00
12.00%
Profit Before Taxation & Exceptional Items
257.00
507.00
-250.00
-49.31%
Exceptional Income / Expenses
0.00
0.00
0.00
0%
Profit Before Tax
252.00
507.00
-255.00
-50.30%
Provision for Tax
64.00
110.00
-46.00
-41.82%
Profit After Tax
187.00
396.00
-209.00
-52.78%
Extraordinary Items
0.00
0.00
0.00
0%
Adj to Profit After Tax
0.00
0.00
0.00
0%
Profit Balance B/F
632.00
1,634.00
-1,002.00
-61.32%
Profit Available for appropriations
820.00
2,031.00
-1,211.00
-59.63%
Appropriations
820.00
2,031.00
-1,211.00
-59.63%
Equity Dividend (%)
1800%
400%
1,400.00
Earnings Per Share
75.01
52.17
22.84
43.78%
Profit And Loss - Net Sales
Net Sales 2,275.58 Cr
in Mar 2026Figures in Cr
YoY Growth in year ended Mar 2026 is 32.59% vs 32.48% in Mar 2025
Profit And Loss - Operating Profit (PBDIT)
Operating Profit (PBDIT) 262.03 Cr
in Mar 2026Figures in Cr
YoY Growth in year ended Mar 2026 is 3.17% vs 37.69% in Mar 2025
Profit And Loss - Interest
Interest 4.49 Cr
in Mar 2026Figures in Cr
YoY Growth in year ended Mar 2026 is 207.53% vs 21.67% in Mar 2025
Profit And Loss - Profit After Tax
Profit After Tax 187.52 Cr
in Mar 2026Figures in Cr
YoY Growth in year ended Mar 2026 is 62.02% vs -28.34% in Mar 2025